Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders

Fillmore, Nathanael R.; La, Jennifer; Wu, Julie Tsu-Yu; Corrigan, June K.; Branch-Elliman, Westyn; Monach, Paul; Brophy, Mary T.; Do, Nhan V.; Munshi, Nikhil C.

doi:10.1182/bloodadvances.2023011063

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In COVID-19, evidence suggests that patients with some types of immunosuppression (e.g., associated with ongoing receipt of cytotoxic chemotherapy or receipt of multiple immunosuppressive medications) remain at higher risk of severe disease when compared to patients with other risk profiles. 26 , 27 It is possible that patients with different types of immunosuppression may exhibit differential treatment responses to immunomodulators that were not able to measure in this study. Patients with different types of immunosuppression also have variable antibody response to mRNA vaccination against COVID-19.…”

Section: Discussionmentioning

confidence: 99%